GB0801888D0 - Treatment of mast cell related disorders - Google Patents

Treatment of mast cell related disorders

Info

Publication number
GB0801888D0
GB0801888D0 GBGB0801888.9A GB0801888A GB0801888D0 GB 0801888 D0 GB0801888 D0 GB 0801888D0 GB 0801888 A GB0801888 A GB 0801888A GB 0801888 D0 GB0801888 D0 GB 0801888D0
Authority
GB
United Kingdom
Prior art keywords
treatment
related disorders
mast cell
cell related
mast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0801888.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GBGB0801888.9A priority Critical patent/GB0801888D0/en
Publication of GB0801888D0 publication Critical patent/GB0801888D0/en
Priority to PCT/GB2009/050091 priority patent/WO2009095719A2/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/31Combination therapy
GBGB0801888.9A 2008-02-01 2008-02-01 Treatment of mast cell related disorders Ceased GB0801888D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0801888.9A GB0801888D0 (en) 2008-02-01 2008-02-01 Treatment of mast cell related disorders
PCT/GB2009/050091 WO2009095719A2 (en) 2008-02-01 2009-01-30 Treatment of mast cell related disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0801888.9A GB0801888D0 (en) 2008-02-01 2008-02-01 Treatment of mast cell related disorders

Publications (1)

Publication Number Publication Date
GB0801888D0 true GB0801888D0 (en) 2008-03-12

Family

ID=39204086

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0801888.9A Ceased GB0801888D0 (en) 2008-02-01 2008-02-01 Treatment of mast cell related disorders

Country Status (2)

Country Link
GB (1) GB0801888D0 (en)
WO (1) WO2009095719A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008222602B2 (en) 2007-03-05 2013-06-20 The University Of Queensland A target for breast cancer therapy and/or diagnosis
TWI412369B (en) * 2010-06-07 2013-10-21 Univ Kaohsiung Medical Pharmaceutical composition for inhibiting cancer cell inflammation
WO2014153241A1 (en) * 2013-03-14 2014-09-25 The Regents Of The University Of Michigan Treatment of staphylococcal disorders
EP2865758A1 (en) 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene
US10351624B2 (en) * 2014-08-07 2019-07-16 Daiichi Sankyo Company, Limited Anti-Orai1 antibody

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751139B2 (en) * 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative

Also Published As

Publication number Publication date
WO2009095719A3 (en) 2010-05-06
WO2009095719A2 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
ZA201008392B (en) Treatment of pluripotent cells
IL217901A0 (en) Treatment of bdnf-related disorders using laquninimod
IL211312A0 (en) Treatment of stroke using isolated placental cells
IL217824A0 (en) Treatment of of macrophage-related disorders
IL208354A0 (en) Methods of treatment
GB0915515D0 (en) Treatment of vasculoproliferative conditions
ZA201102604B (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
HK1160925A1 (en) Use of athepsin
GB0901456D0 (en) Treatment of psoriasis
IL213607A0 (en) 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
GB0900599D0 (en) Treatment
GB0801888D0 (en) Treatment of mast cell related disorders
GB201013898D0 (en) Well treatment
IL200753A0 (en) Treatment of psoriasis
EP2240192A4 (en) Treatment for dermatological conditions
GB0723100D0 (en) Treatment of HFnEF
IL210558A0 (en) Treatment of anxiety disorders
GB201001521D0 (en) Treatment
GB0913968D0 (en) Treatment
HK1157387A1 (en) Use of hsa-producing cells
GB0819446D0 (en) Treatment of inflammatory disorders
GB0809816D0 (en) Treatment of ringworm
GB0808623D0 (en) Treatment of keratinizing disorders
GB0816652D0 (en) Cell therapy
GB0814322D0 (en) Treatment of lysosomal storage disorders

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)